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Background: Global assessment of antimicrobial agents prescribed to infants in the neonatal intensive care
unit (NICU) may inform antimicrobial stewardship efforts.
Methods: We conducted a one-day global point prevalence study of all antimicrobials provided to NICU
infants. Demographic, clinical, and microbiologic data were obtained including NICU level, census, birth
weight, gestational/chronologic age, diagnoses, antimicrobial therapy (reason for use; length of therapy),
antimicrobial stewardship program (ASP), and 30-day in-hospital mortality.
Findings: On July 1, 2019, 26% of infants (580/2,265; range, 0100%; median gestational age, 33 weeks;
median birth weight, 1800 g) in 84 NICUs (51, high-income; 33, low-to-middle income) from 29 countries
(14, high-income; 15, low-to-middle income) in five continents received 1 antimicrobial agent (92%, anti-
bacterial; 19%, antifungal; 4%, antiviral). The most common reasons for antibiotic therapy were “rule-out”
sepsis (32%) and “culture-negative” sepsis (16%) with ampicillin (40%), gentamicin (35%), amikacin (19%),
vancomycin (15%), and meropenem (9%) used most frequently. For definitive treatment of presumed/con-
firmed infection, vancomycin (26%), amikacin (20%), and meropenem (16%) were the most prescribed agents.
Length of therapy for culture-positive and “culture-negative” infections was 12 days (median; IQR, 814)
and 7 days (median; IQR, 510), respectively. Mortality was 6% (42%, infection-related). An NICU ASP was
associated with lower rate of antibiotic utilization (p = 0¢02).
Interpretation: Global NICU antibiotic use was frequent and prolonged regardless of culture results. NICU-spe-
cific ASPs were associated with lower antibiotic utilization rates, suggesting the need for their implementa-
tion worldwide.
Funding: Merck & Co.; The Ohio State University College of Medicine Barnes Medical Student Research Schol-
arship
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Implications of all the available evidence
The finding that NICU-specific antimicrobial stewardship pro-
grams had a positive impact on antibiotic utilization highlights
the potential value of such programs to reduce antibiotic con-
sumption and possibly minimize the adverse effects of antimi-
crobial overuse in high-risk infants. In addition, global
assessment of all antimicrobial use provided to infants in the
NICU and reasons for their use should inform future antimicro-
bial stewardship efforts.1. Introduction
Antimicrobial agents are the most prescribed medications in
the neonatal intensive care unit (NICU) [1,2]. When used for
proven infections, antibiotics have dramatically improved survival
in this high-risk population [3,4]. However, by presumed disrup-
tion of the infant’s bacterial microbiome, antibiotic overuse has
been associated with adverse patient outcomes such as late-onset
sepsis, invasive candidiasis, necrotizing enterocolitis, bronchopul-
monary dysplasia, retinopathy of prematurity, neurodevelopmen-
tal impairment, and even death [513]. In addition, antibiotic
overuse can result in unit-level and public health consequences
such as emergence of multi-drug resistant organisms and higher
health-care costs [14,15]. Despite this knowledge and associa-
tions, the use of antibiotic therapy in NICUs varies widely among
institutions in the United States irrespective of level of NICU care,
medical morbidities, and proven bloodstream infection [1618].
Although it is likely that similar variation exists among NICUs
worldwide [1924], there has been little focus on why and how
antibiotics are used on a global scale.
4 P. Prusakov et al. / EClinicalMedicine 32 (2021) 100727Accordingly, the objectives of the NO-More-AntibioticS and Resis-
tance (NO-MAS-R) study was to 1) determine a single day global
prevalence of all antimicrobial use and specific agents provided to
infants in the NICU; 2) quantify the clinical diagnoses why infants
received antimicrobial therapy; and 3) quantify the proportion of
antibiotics that were started empirically, targeted to an identified
pathogen, or used for prophylaxis. We hypothesized that a substan-
tial proportion of infants in NICUs worldwide would be exposed to
antimicrobial therapy. Our ultimate goal was that global assessment
of all antimicrobial use provided to infants in the NICU and reasons
for their use will inform future antimicrobial stewardship efforts.
2. Methods
2.1. Design and setting
This cross-sectional, observational study enrolled all infants who
were in the NICU and prescribed at least one antimicrobial agent as
of 8 AM or later (local time) on July 1, 2019, the birthday of Ignaz
Semmelweiss, MD, the “Father of Hand Hygiene” and “Savior of
Mothers and Newborns [25].” Pediatricians, neonatologists, pediatric
infectious diseases specialists, and pediatric pharmacists from around
the world were queried to determine their interest in participating in
a survey of antibiotic practices in infants admitted to Level II, III, or IV
NICUs. These classifications of neonatal inpatient care consist of
increasing level of specialty care (Level II) and subspecialty intensive
care (Levels III and IV) [26]. Infants in Level II NICUs are born at 32
weeks’ gestation weighing 1500 g with medical problems that are
expected to resolve rapidly. Level III NICUs are able to provide sus-
tained life support for the most complex and critically ill infants <32
weeks’ gestation, weighing <1500 g at birth, or have medical or sur-
gical conditions regardless of gestational age. Level IV NICUs have the
capabilities of a Level III NICU plus provide on-site surgical repair of
serious congenital or acquired malformations.
2.2. Participants and study procedures
The following data were collected on each infant: pertinent demo-
graphic and clinical information including birth weight, gestational
and chronologic age, diagnoses, name of antimicrobial agent(s) pre-
scribed and received, routes of administration, reason for its use,
planned length of therapy, and culture results. In addition, informa-
tion was obtained on the geographic location of the NICU, NICU level,
NICU census, referral or delivery NICU, and existence of an antimicro-
bial stewardship program (ASP) either in the hospital or specific to
the NICU. An NICU-specific ASP consisted of dedicated personnel in
the NICU who supervise antibiotic use and/or had specific guidelines
on antimicrobial use for the NICU. Finally, a 30-day follow-up assess-
ment was performed to determine actual length of antimicrobial
therapy for each agent prescribed as well as infant outcomes (dis-
charged home, transferred to another facility, or in-hospital death).
In addition, the infection-related in-hospital mortality was assessed
at 30 days by review of the attending physician’s documentation in
the medical record and/or autopsy report if available. The 30-day
mortality has been the standard used by the Centers for Medicare &
Medicaid Services of the United States to assess quality of medical
and surgical care and has been used in pediatric patients for assess-
ment of sepsis mortality [27,28]. Antibiotic use was compared among
infants who were less than three days of age versus those three days
of age or older in keeping with evaluations for early vs. late-onset
infections and sepsis, respectively.
Diagnostic terms were defined to assure consistency among sites.
An antimicrobial agent was defined as a drug that exhibits activity
against a bacterial, fungal, or viral pathogen. Prophylactic therapy
was defined as an antimicrobial agent prescribed to prevent an infec-
tion. Empiric therapy was defined as initiation of an antimicrobialagent for suspected infection with the intent of discontinuing such
therapy once infection was ruled out. Definitive therapy was defined
as antimicrobial therapy that was continued to cure an infection that
was substantiated by clinical and/or microbiologic diagnostics. “Rule-
out sepsis” was defined as initiation of antimicrobial therapy for
infants who were undergoing evaluation for a possible bloodstream
infection with intent to discontinue therapy if the culture(s) were
sterile at 24 to 72 h. “Culture-negative” sepsis or meningitis was
defined as a clinical diagnosis of a bloodstream or central nervous
system infection, respectively, with sterile bacterial cultures and no
viral or fungal pathogen identified.
Antibiotics were grouped by the Access, Watch, Reserve
(“AWaRe”) classification on the basis of the World Health Organiza-
tion’s (WHO) Essential Medicines List for Children and their use com-
pared among NICUs in Asia, Europe, Africa, North America, Central
America, and South America [21,29,30]. The Access group contains
more narrow-spectrum antibiotics, the Watch group contains
broader spectrum antibiotic classes, and the Reserve group consists
of antibiotics reserved for multidrug resistant infections.
2.3. Data sources
The study survey and data were collected and managed using
REDCap (Research Electronic Data Capture), a secure, web-based soft-
ware platform hosted at Nationwide Children's Hospital [31,32]. A
study investigator at each site entered de-identified data either real
time or retrospectively if real time entry was not feasible. In case of
technical difficulties with REDCap, local site investigators entered de-
identified data using an Excel spreadsheet that was subsequently
entered into REDCap by the study coordinator at Nationwide Child-
ren’s Hospital. The data collection tool was piloted on December 12,
2018 with 12 international sites to identify any data collection chal-
lenges. Modifications were made based on participants’ feedback.
Although we were not able to perform external data validation at
each site, procedures were implemented to minimize data entry
errors. Each participating site was provided a Manual of Operations
with standard definitions, the REDCap data entry had restriction on
numbers entered, all names of antimicrobial agents were selected
from a drop-down menu, and the Excel database had prefilled
parameters to facilitate data acquisition. In addition, we queried sites
if there was concern for entered data.
2.4. Ethics statement
The study was approved by the Institutional Review Board (IRB) at
Nationwide Children's Hospital under the following designated num-
ber: STUDY00000208. Invitation letter, study protocol in English or
Spanish, and the Nationwide Children’s Hospital IRB approval letter
were provided to each participating site for submission to the local
IRB. Each site was responsible for obtaining ethics approval if
required by their institution. Since all data were anonymized without
patient identifiers and there was no direct contact with patients, the
study at all sites was exempt from the need to obtain informed
consent.
2.5. Statistical analysis
Descriptive statistics and graphical presentation of the data were
done by means of Microsoft Excel. Comparative statistical analyses
were performed using IBM SPSS Statistics for Windows, Version 26¢0.
Armonk, NY: IBM Corp. For categorical data, chi-squared or Fisher
exact tests were used for comparison as well as analysis of depen-
dence. For normally distributed continuous data, means with stan-
dard deviation were derived for descriptive statistics and analyzed
with two-sample t-test [33]. All nonparametric data were reported as
median with interquartile range (IQR) and analyzed with
P. Prusakov et al. / EClinicalMedicine 32 (2021) 100727 5independent-samples Mann-Whitney U test. For accuracy, missing
data were not imputed.
2.6. Role of the funding source
The funding agency had no influence on study design, data collec-
tion, or analysis. The corresponding author had full access to the data
and is responsible for the decision to submit for publication.
3. Results
3.1. Demographics
On July 1, 2019, 580 (26%) of 2265 infants in 84 hospital NICUs in
29 countries (14 high and 15 low-to-middle income countries, Fig. 1)
received at least one antimicrobial agent. Of the 84 NICUs, 51 (61%)
and 33 (39%) were in high and low-to-middle income countries,
respectively, with a median of 5 infants per site in both high (IQR,
29) and low-to-middle (IQR, 39) income countries. Sixty-two
(74%) NICUs were in hospitals that had a labor and delivery service
and the rest in referral centers that cared for outborn infants. All but
4 NICUs were Level 3 (n = 42, 50%) or Level 4 (n = 38; 46%). The anti-
microbial utilization per NICU in low-to-middle income countries
(31%, median; IQR, 17%48%) was significantly greater than in NICUs
of high-income countries (18%, median; IQR, 10%36%; p = 0¢0013).
Of the 580 infants who received an antimicrobial agent, 83% were
3 days of age, the median gestational age was 33 weeks (IQR,
2837 weeks), median birth weight was 1800 g (IQR, 10602840 g),
and median postnatal age was 11 days (IQR, 433 days) (Table 1).
Most of the infants were male (59%) and 23% (n = 133) were <28
weeks’ gestation (Table 1). Their characteristics and outcome by
global region are provided in Supplementary Table 1. Antibacterials
were the most frequently used antimicrobial agents with 92%Fig. 1. Map of the 29 countries that participated in the NO-More-AntibioticS and Resistance
unit (NICU) who received at least one antimicrobial agent on July 1, 2019, the birthday of Ign
on antimicrobial therapy) by level of income were: High income, Belgium (n = 1; 3), Canada
(n = 13; 77), Japan (n = 3; 12), Netherlands (n = 1; 9), Oman (n = 1; 3), Panama (n = 1; 1), Spain
tina (n = 2; 10), Brazil (n = 1; 13), China (n = 1; 21), Colombia (n = 12; 43), Costa Rica (n = 1; 5)
Lebanon (n = 1; 2), Mexico (n = 1; 8), Nigeria (n = 3; 43), Peru (n = 2; 14), South Africa (n = 2; 5(n = 531) of infants receiving 940 antibiotics on the assessment day
(Table 2), 19% (n = 108) receiving 108 antifungal agents, and 4%
(n = 25) received 25 antiviral medications.
3.2. Antibacterial therapy
The majority of infants (55%, 293/531) received an antibacterial
agent(s) as empiric therapy for possible infection while 38% (n = 204/
531) received antibiotic(s) for a specific infection-related diagnosis
and 6% (n = 34/531) for prophylaxis. The most frequent reason for
infants receiving antibiotics was for possible sepsis (“rule-out sepsis”;
32%; n = 168/531) with the majority (66%; n = 111) of these infants
being 3 days of age (Fig. 2). The second most frequent reason was
“culture-negative” sepsis/meningitis (16%; n = 87). Only 20% of
infants received antibacterial therapy for culture-confirmed infection
(15%; n = 80, culture-proven sepsis/meningitis; 4%; n = 21, culture-
proven urinary tract infection (UTI); 1%; n = 5 had both; Table 3). The
most common single organisms detected in blood were coagulase-
negative staphylococci (n = 32; 29%) and Klebsiella pneumoniae
(n = 24; 22%) while in urine, Klebsiella spp. (n = 12; 39%) and Escheri-
chia coli (n = 7; 23% Table 3) were the most frequent pathogens. Other
indications for antibacterial therapy were pneumonia/tracheitis (15%;
n = 82), NEC (8%; n = 42), surgical site infection (4%; n = 23), and con-
genital syphilis (2%; n = 12).
Among the 531 infants who received antibacterial therapy, ampi-
cillin (40%, n = 211), gentamicin (35%, n = 185), and amikacin (19%,
n = 101) were most frequently prescribed (Table 2). Among the 38%
(204/531) of infants on definitive antibacterial therapy, vancomycin
(26%, n = 53), amikacin (n = 20%, n = 40), and meropenem (16%,
n = 32) were the most prescribed agents. An additional 35 (17%)
infants received third and fourth generation cephalosporins. Access
antibiotics were used more frequently by Africa, South America,
North America, and Central America while Europe and Asia used(NO-MAS-R) study, a point prevalence study of all infants in the neonatal intensive care
az Semmelweiss, MD. Participating countries (number of NICUs; total number of infants
(n = 2; 5), Chile (n = 4; 38), Finland (n = 1; 10), Greece (n = 1; 5), Israel (n = 2; 14), Italy
(n = 5; 35), Sweden (n = 1; 4), United States (n = 15; 84); Middle-to-Low Income, Argen-
, Ecuador (n = 3; 12), Ghana (n = 1; 10), Guyana (n = 1; 9), Haiti (n = 1; 29), Iran (n = 1; 3),
8).
Table 1
Characteristics and outcome of the 580 infants who received antimicrobial therapy in the neonatal intensive care unit on July 1, 2019.
Infants in Neonatal Intensive Care Unit






No. of infants 60 (60%) 40 (40%) 100 (17%) 220 (46%) 260 (54%) 480 (83%) 580
Birth weight (grams, IQR) 2680 (17203110) 2208 (15753078) 2400 (16803100) 2253, 12002914 1350, 8002460 1680 (9952771) 1800 (10602835)
1000 3 (50%) 3 (50%) 6/100 (6%) 23 (18%) 102 (82%) 125/477 (26%) 131/577 (23%)
10011500 5 (42%) 7 (58%) 12/100 (12%) 50 (54%) 43 (46%) 93/477 (20%) 105/577 (18%)
15012500 20 (63%) 12 (38%) 32/100 (32%) 54 (51%) 51 (49%) 105/477 (22%) 137/577 (24%)
2501 32 (64%) 18 (36%) 50/100 (50%) 91 (59%) 63 (41%) 154/477 (32%) 204/577 (35%)
Chronologic age (days, IQR) 1 (12) 1 (12) 1 (12) 10 (527) 21 (961) 16 (640) 11 (433)
Gestational age (weeks, IQR) 36 (3239) 34 (3137) 34 (3238) 34 (3036) 30 (2636) 32 (2737) 33 (2837)
28 weeks 3 (33%) 6 (67%) 9/93 (10%) 38 (26%) 109 (74%) 147/474 (31%) 156/567 (28%)
2933 weeks 14 (56%) 11 (44%) 25/93 (27%) 59 (50%) 58 (50%) 117/474 (25%) 142/567 (25%)
3436 weeks 14 (54%) 12 (46%) 26/93 (28%) 39 (50%) 39 (50%) 78/474 (16%) 104/567 (18%)
37 weeks 22 (67%) 11 (33%) 33/93 (35%) 79 (60%) 53 (40%) 132/474 (28%) 165/567 (29%)
Sex, male 33 (63%) 19 (37%) 52 (52%) 132 (46%) 156 (54%) 288 (60%) 340 (59%)
Race/ethnicity
White 1 (4%) 25 (96%) 26 (26%) 1 (1%) 138 (99%) 139 (29%) 165 (28%)
Black 29 (100%) 0 29 (29%) 106 (82%) 23 (18%) 129 (27%) 158 (27%)
Hispanic 16 (76%) 5 (24%) 21 (21%) 81 (64%) 45 (36%) 126 (26%) 147 (25%)
Asian 5 (50%) 5 (50%) 10 (10%) 12 (50%) 12 (50%) 24 (5%) 34 (6%)
Other 4 (57%) 3 (43%) 7 (7%) 14 (33%) 29 (67%) 43 (9%) 50 (9%)
Unknown 5 (71%) 2 (29%) 7 (7%) 6 (32%) 13 (68%) 19 (4%) 26 (4%)
MDRO colonization
MRSA 0 0 0 1 (25%) 3 (75%) 4 (1%) 4 (1%)
VRE 0 0 0 0 1 (100%) 1 (1%) 1 (1%)
CRE 0 0 0 1 (100%) 0 1 (1%) 1 (1%)
ESBL-Enterobacteriaceae 0 0 0 7 (88%) 8 (12%) 15 (3%) 15 (3%)
Respiratory support
None 26 (62%) 16 (38%) 42/91 (46%) 92 (56%) 71 (44%) 163/454 (36%) 204/545 (38%)
Any 27 (55%) 22 (45%) 49/91 (54%) 112 (38%) 179 (62%) 291/454 (64%) 340/545 (62%)
Nasal cannula 15 (94%) 1 (6%) 16 (18%) 45 (61%) 29 (39%) 74 (15%) 90 (17%)
CPAP 4 (29%) 10 (71%) 14 (15%) 29 (37%) 49 (63%) 78 (16%) 92 (16%)
Mechanical ventilation 8 (42%) 11 (58%) 19 (21%) 37 (28%) 94 (72%) 131 (27%) 150 (26%)
Tracheostomy 0 0 0 (0%) 1 (13%) 7 (88%) 8 (2%) 8 (1%)
Central venous catheter 8 (32%) 18 (72%) 26 (26%) 61 (29%) 151 (72%) 212 (44%) 238 (41%)
Urinary catheter 0 4 (100%) 4 (4%) 6 (19%) 25 (81%) 31 (6%) 35 (6%)
Probiotic 1 (25%) 3 (75%( 4 (4%) 4 (3%) 27 (87%) 31 (6%) 35 (6%)
Lactoferrin 0 1 (100%) 1 (1%) 0 8 (100%) 8 (2%) 9 (2%)
Acid suppression medication 4 (100%) 0 4 (4%) 11 (26%) 31 (74%) 42 (9%) 46 (8%)
Mortality-30 day 3 (60%) 2 (40%) 5 (5%) 13 (46%) 15 (54%) 28 (6%) 33 (6%)
Infection-related 1 (33%) 2 (67%) 3 (60%) 6 (55%) 5 (45%) 11 (39%) 14 (42%)
IQR, interquartile range; MDRO, multi-drug resistant organism; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci; CRE, carbapenem-resis-
tant Enterobacteriaceae; ESBL, extended-spectrum beta-lactamase; CPAP, continuous positive airway pressure.
6 P. Prusakov et al. / EClinicalMedicine 32 (2021) 100727more Watch antibiotics. Reserve antibiotics were used only by
Europe and South America (Fig. 3).
At the initial assessment, the planned length of treatment was
reported in the medical record for 475 (89%) of the 531 infants on
antibiotics. The planned length of therapy was indicated as indefinite
(15%, n = 72), 1 to 3 days (24%, n = 113), 4 to 6 days (10%, n = 49), 7
days (23%, n = 109), 10 days (12%, n = 59), 14 days (10%, n = 48), 21
days (3%, n = 16), or 4 to 6 weeks (2%, n = 9) for planned length of
antibiotic therapy. The final length of therapy was reported on 405
(85%) of the 475 infants when assessed on follow-up at 30 days. The
actual length of therapy was 7 days (median; IQR, 512 days) overall,
with infants who received definitive treatment receiving 10 days
(median; IQR, 715 days). Final length of therapy for culture-positive
and culture-negative infections without concomitant diagnosis of
meningitis was 12 days (median; IQR, 814 days) and 7 days
(median; IQR, 510 days), respectively. Length of therapy for pneu-
monia was 7 days (median; IQR, 510 days), for UTI was 7 days
(median; IQR, 714 days), and for NEC, 9 days (median; IQR, 715
days).
Length of antibiotic therapy for any indication did not differ
between NICUs with or without NICU-specific ASPs (7 days [median;
IQR, 513 days] vs. 8 days [median; IQR, 512], respectively;
p = 0¢99) nor was it different between high or low-to-middle incomecountries (7 days [median, [IQR, 412 days] vs. 9 days [median, IQR
513], respectively; p = 0¢29). Similarly, length of antibiotic therapy
for definitive treatment did not differ between NICUs with or without
NICU-specific ASPs (10 days [median; IQR, 714 days] vs. 12 days
[median; IQR, 716 days], respectively; p = 0¢50) or between high vs.
low-to-middle income countries (10 days [median; IQR, 714 days]
vs. 10 days [median; IQR, 715 days], respectively; p = 0¢50) 7 (IQR,
612). For infants >72 h of age, duration of empiric therapy was 7
days (median; IQR, 510) and 10 days for definitive treatment
(median; IQR, 714). Duration of therapy with antibacterial agents
for prophylaxis among infants was 16 days (median; IQR, 756).
3.3. Antifungal therapy
Of the 108 infants who received antifungal agents (fluconazole
[59%, n = 64], amphotericin B deoxycholate [19%, n = 21], nystatin
[18%, n = 19], amphotericin B liposomal [2%, n = 2], caspofungin [1%,
n = 1], unknown [1%, n = 1]), the main indication was prophylaxis
(62%, n = 67). Of the remaining 41 infants who received antifungal
therapy, “rule-out sepsis” (54%; n = 22), sepsis (17%; n = 7), and skin/
soft tissue infections (10%; n = 4) were the most common indications.
Definitive antifungal treatment for culture-confirmed fungal infec-
tion consisted mainly of fluconazole and amphotericin B
Table 2
Antibacterial therapy (n = 940) provided to 531 (23%) of 2265 infants in the neonatal intensive care unit of 84 hospitals in 29
countries grouped by the World Health Organization AWaRe classification.*
*Antibiotics were grouped by the AWaRE (Access, Watch, and Reserve) classification on the basis of the WHO Essential Medi-
cines List for Children. The Access group contains narrower-spectrum antibiotics, the Watch group contains broader spectrum
antibiotic classes, and the Reserve group consist of antibiotics reserved for multidrug resistant infections.
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Fig. 2. Indications for antibiotic use among the 531 infants, with the percentage of infants who received antibacterial therapy for that indication on the x-axis.
8 P. Prusakov et al. / EClinicalMedicine 32 (2021) 100727deoxycholate therapy. Infants on definitive therapy with antifungal
agents accounted for 17% (n = 18) of their use. Of the seven (n = 580;
1%) infants treated for systemic disease and had positive cultures for
yeast (6, Candida spp. and 1 yeast not identified), 4 received flucona-
zole and 3 received amphotericin B deoxycholate. Of 67 patients who
were on antifungal prophylaxis, the majority were extremely low
birth weight infants, less than 1000 gs (69%; n = 46). Overall, 24 (29%)
of the 84 hospital NICUs utilized fluconazole prophylaxis.
3.4. Antiviral therapy
Among the 25 infants who received antiviral agents, the main
indication was prophylaxis (72%, n = 18) for exposure to maternal
infection with human immunodeficiency virus and all received zido-
vudine monotherapy. Of the remaining seven infants, 5 received acy-
clovir (2, empiric; 3, treatment), 1 received ganciclovir for
cytomegalovirus infection, and in one infant the specific antiviral
agent was not known.
3.5. Other analyses
A hospital-wide ASP that included the NICU was present in 62%
(n = 50/81) of hospitals (31 high-income and 19 low-to-middle
income countries; p = 0¢95). An NICU-specific ASP was present in 52%
(40/77) of NICUs (23 high-income and 17 low-to-middle income
countries; p = 0¢47). Eight hospitals with NICU-specific ASP did not
have a hospital-wide ASP. NICUs with their own ASP had significantly
lower median rates of antibiotic utilization compared to those with-
out one (18% vs. 29%, respectively; p-value=0¢02). Similarly, these
NICUs with ASP also had fewer antibiotic utilization per patient
(1¢4 vs. 1¢7 antibiotics/patient) and used less Access antibiotics
(0¢89 vs. 1¢2 antibiotic/patient) but similar Watch antibiotics (0¢53 vs.
0¢45 antibiotic/patient).
Eleven (2%) infants received probiotics and three had bloodstream
infections with coagulase-negative staphylococci and two with
Staphylococcus aureus, while one had NEC. Three (0¢05%) infantsreceived lactoferrin and two had bloodstream infections with coagu-
lase-negative staphylococci and one with S. aureus while the third
had staphylococcal osteomyelitis. Among the 46 (8%) infants who
received acid suppression medications, 14 had bloodstream infection
(7, coagulase-negative staphylococci; 2, S. aureus; 3, Klebsiella pneu-
moniae; 1, Streptococcus pneumoniae; 1 polymicrobial with Stenotro-
phomonas maltophilia and coagulase-negative staphylococci).
3.6. Outcomes
Mortality at 30 days was 6% (33/580) and did not differ between
infants who received antimicrobial agents in the first 48 h of age (5%;
n = 5) versus those who were 72 h of age (6%; n = 28; Table 1). The
percentage of deaths that were assessed as infection-related also was
not different between the two groups (60% [3/5] vs. 39% [11/28],
respectively). Of the 33 deaths, 42% (n = 14) were assessed as being
related to infection.
4. Discussion
On July 1, 2019, 26% of high-risk infants in NICUs worldwide
received at least one antimicrobial agent, mostly antibacterials and in
those cared for in low-to-middle income countries. The majority of
the infants received antibiotic therapy as empiric coverage for possi-
ble sepsis, although a substantial number were treated for “culture-
negative” sepsis/meningitis and only a minority for culture-con-
firmed infection. Importantly, hospitals that had an NICU-specific
ASP had significantly lower antibiotic utilization rates. The impor-
tance of such a program cannot be over-emphasized as it ultimately
may help to decrease antimicrobial resistance in NICUs worldwide
[3446].
Infants often received antimicrobial therapy based on clinical sus-
picion of a serious bacterial infection rather than on positive bacterial
culture results. After excluding antibiotics provided for prophylaxis
and empiric therapy, 49% of infants received prolonged antibiotic
therapy without microbiologic evidence of infection. The notion of
Table 3
Pathogens detected in blood and urine of the 580 infants who received antimicrobial therapy in the neonatal intensive care unit on July 1, 2019.
Infants in Neonatal Intensive Care Unit
<3 Days Old 3 Days Old Total
Country income Low-to-Middle Income High Income Total Low-to-Middle Income High Income Total
No. of infants 60 (60%) 40 (40%) 100 (17%) 220 260 480 (83%) 580
No. of pathogens in blood: 3 (50%) 3 (50%) 6 (6%) 46 59 105 (22%) 111 (19%)
Gram-positive 2 (50%) 2 (50%) 4 (67%) 17 31 48 (46%) 52 (47%)
Coagulase-negative staphylococci (CoNS)* 0 2 2 (33%) 8 22 30 (29%) 32 (29%)
Streptococcus pneumoniae 0 0 0 8 0 8 (8%) 8 (7%)
Staphylococcus aureus 2 0 2 (33%) 1 4 5 (5%) 7 (6%)
Group B Streptococcus 0 0 0 0 2 2 (2%) 2 (2%)
Bacillus cereus 0 0 0 0 2 2 (2%) 2 (2%)
Enterococcus faecalis 0 0 0 0 1 1 (1%) 1 (1%)
Gram-negative 1 1 2 (33%) 23 20 43 (47%) 45 (41%)
Klebsiella spp* 1 0 1 (17%) 11 12 23 (22%) 24 (22%)
E. coli 0 1 1 (17%) 3 3 6 (6%) 7 (6%)
Pseudomonas aeruginosa 0 0 0 3 1 4 (4%) 4 (4%)
Enterobacter cloacae 0 0 0 1 2 3 (3%) 3 (3%)
Serratia marcescens 0 0 0 1 1 2 (2%) 2 (2%)
Acinetobacter species 0 0 0 2 0 2 (2%) 2 (2%)
Stenotrophomonas maltophilia 0 0 0 0 1 1 (1%) 1 (1%)
Pseudomonas fluorescens 0 0 0 1 0 1 (1%) 1 (1%)
Alcaligenes faecalis 0 0 0 1 0 1 (1%) 1 (1%)
Fungi 0 0 0 4 1 5 (%) 5 (5%)
Candida parapsilosis 0 0 0 2 1 3 (3%) 3 (3%)
Candida albicans 0 0 0 1 0 1 (1%) 1 (1%)
Yeast not identified 0 0 0 1 0 1 (1%) 1 (1%)
Polymicrobial 0 0 0 2 6 8 (8%) 8 (7%)
E. coli, CoNS 0 0 0 1 1 2 (2%) 2 (2%)
C. albicans, C. lusitaniae 0 0 0 0 1 1 (1%) 1 (1%)
S. maltophilia, CoNS 0 0 0 0 1 1 (1%) 1 (1%)
C. albicans, K. pneumoniae* 0 0 0 0 1 1 (1%) 1 (1%)
E. faecalis, K. pneumoniae 0 0 0 0 1 1 (1%) 1 (1%)
K. pneumoniae, P. aeruginosa, CoNS 0 0 0 0 1 1 (1%) 1 (1%)
B. pertussis, S. pneumoniae 0 0 0 1 0 1 (1%) 1 (1%)
Enterovirus* 0 0 0 0 1 1 (1%) 1 (1%)
No. of pathogens in urine 0 0 0 12 19 31 (6%) 31 (5%)
Gram-positive 0 0 0 0 1 1 (3%) 1 (3%)
Enterococcus spp. 0 0 0 0 1 1 (3%) 1 (3%)
Gram-negative 0 0 0 12 13 25 (81%) 25 (81%)
Klebsiella spp. 0 0 0 6 6 12 (39%) 12 (39%)
E. coli 0 0 0 3 4 7 (23%) 7 (23%)
Enterobacter spp. 0 0 0 0 3 3 (10%) 3 (10%)
P. aeruginosa 0 0 0 2 0 2 (6%) 2 (6%)
Gram negative bacilli, not yet identified 0 0 0 1 0 1 (3%) 1 (3%)
Fungi 0 0 0 0 1 1 (3%) 1 (3%)
C. albicans 0 0 0 0 1 1 (3%) 1 (3%)
Polymicrobial 0 0 0 0 4 4 (13%) 4 (13%)
Klebsiella. spp., Enterococcus spp., S. aureus 0 0 0 0 1 1 (3%) 1 (3%)
Klebsiella spp., Enterococcus spp. 0 0 0 0 1 1 (3%) 1 (3%)
E. coli, CoNS 0 0 0 0 1 1 (3%) 1 (3%)
E. coli, Enterococcus spp. 0 0 0 0 1 1 (3%) 1 (3%)
* Same pathogen also was detected in cerebrospinal fluid: 2, Klebsiella pneumoniae; 1, CoNS; 1, enterovirus
~Pathogens in polymicrobial cultures are not included in the listing of single isolates.
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dispelled from our NICUs [47,48]. Infants in the NICU often experi-
ence prematurity-related events that mimic signs and symptoms of
infection. Performance of full sepsis evaluations (e.g. blood, urine,
cerebrospinal fluid) before initiation of antibiotic therapy, obtaining
sufficient quantity of blood for culture, and investigation of viral and
fungal etiologies should allow comfort in discontinuation of antibiot-
ics if cultures are sterile [4958]. Ultimately, genomic methods for
detection of microbial pathogens in body fluids may allow optimal
identification of infected infants and more appropriate use of antimi-
crobial therapy [59,60].
Overall length of antibiotic therapy was often prolonged (i.e., >
72 h) as 80% (325/405) of infants received a median of 7 days with
definitive treatment for presumed or culture-positive infection being
a median of 10 days. Final length of therapy for culture-positive and
culture-negative infections without concomitant diagnosis of menin-
gitis was 12 days (median; IQR, 814 days) and 7 days (median; IQR,510 days), respectively. Although length of antibiotic therapy
remains an unresolved issue, single center studies have suggested
shorter courses of five total days are safe and effective for “culture-
negative” sepsis and pneumonia [40,6163]. Our study did not find
any differences in length of therapy between centers irrespective of
country, income level, or presence of ASP, confirming the need for
robust research to address this knowledge gap.
Analysis of antibiotic use utilizing the WHO AWaRe classification
revealed similar use of Access antibiotics across NICUs in South
America, North America, and Central America, but higher Watch anti-
biotics in Europe and Asia (Fig. 3). As some broad spectrum agents
such as meropenem are included in the Watch group, further assess-
ment utilizing an antibiotic spectrum index may be a more optimal
tool [30,64,65]. Overall use of Reserve antibiotics was low and these
agents were only used in Europe and South America (Fig. 3).
Fewer infants received antiviral agents in our study with the
majority prescribed for HIV prophylaxis. Similarly, the majority of
Fig. 3. Percentage of total antibiotic use among infants in the neonatal intensive care unit as determined by the World Health Organization AWaRe classification* by a) global region
and b) AWaRe group. *AWaRe = Access, Watch, and Reserve.
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center as only 29% of NICUs utilized prophylactic fluconazole. The
majority of treatment courses were for oral candidiasis, and only 1%
(7/580) of infants were treated for systemic disease with either
amphotericin B deoxycholate (n = 3) or fluconazole (n = 4). A more
targeted assessment of antifungal prophylaxis and treatment is
needed to address needed stewardship in this area [66].
Our novel, single-day, cross-sectional study has limitations. First
of all and inherent in its design, a single-day prevalence study did not
allow assessment of day-to-day variability or longitudinal trends,
and thus the resulting wide uncertainty in antimicrobial use was
demonstrated by the large range (0100%) of infants exposed to anti-
microbial agents in the 84 NICUs. The generalizability of the results
was limited by 48% of the NICUs being from three countries, namely
Colombia, Italy, and the United States. Recruitment of study sites was
a convenient sample done through personal contact with individuals
and centers, many of which have a specific interest in neonatal infec-
tious diseases. It is therefore possible that our study may underesti-
mate the actual use of antimicrobials globally especially among
centers not devoted to antimicrobial stewardship. Similar studiesperformed at a national level in Greece and Australia showed higher
prevalence of antimicrobial use that ranged from 40% to 46%, respec-
tively [19,22]. We also did not conduct personal interviews with pre-
scribers to fully understand the rationale for initial and continuation
of antimicrobial use beyond what was stated in the infant’s medical
record. Specific antibiotic mean inhibitory concentrations for
detected pathogens also was not obtained in order to optimally
assess use of more broad-spectrum agents in the Watch and Reserve
groups. We did not query sites concerning antibiotic shortages or
supply that could have influenced the type of antimicrobial agent(s)
used. Finally, the proportion of infants who received probiotics and
lactoferrin could not be ascertained since the number of infants who
received them without receiving antimicrobial agents was not
obtained.
In conclusion, we found that more than a quarter of infants in
NICUs globally received at least one antimicrobial agent. Although
the antibiotic utilization was lower in high-income countries, centers
that had an NICU-specific ASP had lower antibiotic utilization rates
regardless of the country’s income level. The finding that NICU-spe-
cific ASP had a positive impact on utilization highlights the potential
P. Prusakov et al. / EClinicalMedicine 32 (2021) 100727 11value of such a program to reduce antibiotic consumption and possi-
bly minimize the adverse effects associated with dysbiosis in high-
risk infants.
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